New eye drug shows promise for Diabetes-Related vision loss
NCT ID NCT05940428
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This early-stage trial tests an experimental drug called ASKG712, given as an eye injection, for people with diabetic macular edema (DME) — a condition that causes vision loss in people with diabetes. The study involves 26 participants and focuses on safety and how the drug moves through the body. It is not yet testing for a cure, but aims to control the disease and improve vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, China
Conditions
Explore the condition pages connected to this study.